Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...

PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...

Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...

Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...

This therapy is designed to address the needs of children and adults with aromatic L-amino acid decarboxylase (AADC) ...

Multibagger Stock: PTC Industries, an engineering component manufacturer, has experienced a remarkable surge in its share ...

Improvements to premium tax credits, enacted in the American Rescue Plan and extended by the Inflation Reduction Act, have ...

First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children and adults - - PTC pioneers new approach for CNS drug ...

Travel sourcing and consultancy group Partnership Travel Consulting has named former Corporate Travel Management executive Maureen Brady as its chief commercial officer, a new position for the group.